Achieving Access to High-Quality Care Across the Spectrum of Age and Patient Type to Improve Overall Outcomes for Atopic Dermatitis

CME/CE Accreditation Information Return to Previous

Title of activity: Achieving Access to High Quality Care Across the Spectrum of Age and Patient Type to Improve Overall Outcomes for Atopic Dermatitis

  • Jointly provided by Impact Education, LLC, Partners for Advancing Clinical Education (PACE) and RealCME
  • This activity is supported by an independent educational grants from Sanofi and Regeneron Pharmaceuticals, Inc.
  • Estimated time to complete the activity: 4 hours
  • For additional information about the accreditation of this activity, please visit https://partnersed.com


Target Audience

This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.


Educational Objectives
                                               
Upon completion of this activity, participants should be able to:

  1. Explain the challenges pediatric and adult patients’ experience with moderate-to-severe atopic dermatitis and the recommended treatment options
  2. Assess opportunities to collaborate and apply fair drug coverage policies to atopic dermatitis treatments
  3. Identify opportunities to address elements that contribute to the disparities in access and outcomes in atopic dermatitis


Faculty and Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

 

Faculty

Conflicts of Interest

Joy Wan, MD, MSCE
Assistant Professor of Dermatology
John Hopkins University School of Medicine

Consultant/Advisor/Speaker: Janssen
Researcher: Pfizer
Data Monitoring Committee Member: Sun Pharmaceuticals

Heather Woolery-Lloyd, MD, FAAD
Director, Skin of Color Division
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery
University of Miami Miller School of Medicine

Consultant, Advisor, Speaker: AbbVie, Incyte, Johnson & Johnson Consumer, Inc., L’Oreal, Pfizer, LivDerm, Lilly, Ortho Dermatologics, Uniliver, Procter & Gamble, SC Johnson, Beiersdorf
Researcher: Allergan, Arcutis, Eirion Therapeutics, Galderma, Pfizer, Sanofi, Vyne Therapeutics


Joint Accreditation Statement

 In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC.  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Education
PACE designates this other activity, Gather-ed, for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 4.0 contact hour (0.4 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-24-120-H01-P

Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 4.0 contact hours.


Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 
Instructions for Credit

Participation in this activity should be completed in approximately 4 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 21, 2024 through December 31, 2024:

  • Read the target audience, learning objectives, and faculty disclosures.
  • Study the educational activity.

To claim the maximum amount of credit available, you must complete all of the following:

  • Completion of baseline assessment: 0.50 credit hour
  • Completion of two self-study modules: 0.25 credit hour per module, for a total of 0.50 credit hour
  • Live Group Discussion 1: 0.75 credit hour
  • Live Group Discussion 2: 0.75 credit hour
  • Completion of group challenges (2): 0.5 credit hour per challenge, for a total of 1.00 credit hours
  • Completion of final assessment: 0.50 credit hours


FEE INFORMATION

There is no fee for this educational activity.